When a “Head Start” Becomes Trade Secret Misappropriation: Protecting Pharmaceutical Innovation During Business Discussions

Pharmaceutical innovation often begins long before there is a commercial product. An academic investigator, physician, entrepreneur, or small biotechnology company may identify a promising compound, formulation, drug-delivery system, manufacturing process, or new therapeutic use. But turning that concept into an FDA-approved product requires money, development expertise, manufacturing capabilities, and often a commercial partner.

That creates a familiar problem. To obtain those resources, the inventor must tell other people what he or she has invented.

Suppose an inventor approaches a pharmaceutical company or investor seeking funding or a development partnership. The inventor explains the product concept, shares preliminary data, discusses formulation or manufacturing issues, identifies promising development pathways, and perhaps explains problems that have already been encountered and solved.

The parties ultimately do not reach a deal.

Two years later, the receiving company announces a remarkably similar development program. Worse from the inventor’s perspective, the company appears to have moved faster than the inventor could (or did). It obtained financing, hired a development team, conducted studies, filed patent applications, and perhaps reached the clinic while the original inventor was still attempting to raise money.

The inventor’s reaction may be predictable: “They stole my idea!”

But trade secret law asks a more difficult question:

Did the company steal confidential information, or did it simply learn about an opportunity and then execute faster using information it was legally entitled to use?

Those are very different things.

Trade Secret Law Does Not Protect an Idea Merely Because Someone Thought of It First

The federal Defend Trade Secrets Act (“DTSA”) does not create a general right of ownership over business ideas or scientific concepts. Broadly speaking, information qualifies for federal trade-secret protection only when:

1. the owner has taken reasonable measures to keep the information secret; and
2. the information derives independent economic value from not being generally known or readily ascertainable through proper means.

18 U.S.C. §1839(3).

Misappropriation likewise generally requires improper acquisition, disclosure, or use of the protected information. 18 U.S.C. §1839(5).

That distinction matters. Trade secret law ordinarily does not prohibit a competitor from reading the scientific literature, studying published patents, evaluating publicly disclosed clinical results, conducting its own experiments, reverse engineering where legally permissible, or independently reaching the same commercial conclusion. Indeed, the ability of competitors to learn from publicly available information and compete is part of the bargain underlying both patent and trade-secret law.

The difficult cases arise when public information and confidential information become intertwined.

The Pharmaceutical “Head-Start” Problem

Consider two competing narratives. The inventor says:

“I showed you the opportunity. I explained why the product would work. I gave you my experimental results, formulation knowledge, development strategy, and solutions to technical problems. You declined to invest in me and instead used what I taught you to start your own program. You avoided years of trial and error.”

The recipient says:

“You told us about an interesting scientific opportunity. Much of what you told us was already disclosed in your patents, presentations, publications, or the scientific literature. We raised our own money, hired our own scientists, conducted our own experiments, and developed our own product. You may be disappointed that we executed faster, but successful competition is not trade-secret theft.”

Either narrative can be legally correct. The outcome frequently depends on four questions: (1) What exactly was secret? (2) How was it disclosed? (3) When did it become public? (4) And what exactly did the recipient use?

Pitfall No. 1: “We Talked About It” Is Not the Same as “We Disclosed It in Confidence”

The cleanest situation is a written confidentiality or nondisclosure agreement executed “before” substantive technical information is exchanged. The agreement should do more than prohibit disclosure to outsiders. Particularly in pharmaceutical business-development discussions, it should restrict “use” of the confidential information to a defined purpose, for example, evaluating a potential investment, license, acquisition, collaboration, or development agreement.

That distinction can become critical. A recipient might never disclose the information to anyone outside its organization and nevertheless obtain enormous value by using the information internally to launch or accelerate its own competing development program.

A confidentiality agreement that prohibits unauthorized use and disclosure provides substantially clearer boundaries.

Without a written agreement, an inventor may still attempt to establish an implied confidential relationship or another circumstance imposing a duty of secrecy. But the factual and legal fight becomes much harder. The recipient may contend that no restriction was discussed, that the inventor was pitching an idea rather than disclosing protected know-how, or that the recipient reasonably understood itself to be free to pursue the opportunity independently.

There is also an important mirror image of this problem. A prospective recipient may affirmatively refuse to receive confidential information. A pharmaceutical company, investor, or other organization that routinely evaluates outside opportunities may state that it will not enter into a CDA at the introductory stage, that the inventor should not disclose confidential or proprietary information, and that anything voluntarily disclosed before execution of a written agreement will be treated as nonconfidential.

That practice has analogues in other idea-intensive industries. Literary agents, producers, and entertainment companies, for example, frequently decline unsolicited manuscripts or screenplays, in part to reduce later disputes that independently created material was copied from an unsolicited submission. A pharmaceutical company evaluating numerous compounds, formulations, platforms, and product concepts faces a similar risk: today’s unsolicited pitch can become tomorrow’s accusation that an internal development program was derived from the pitch.

Such a disclaimer is not necessarily an absolute defense. Trade-secret liability ultimately depends on the information, the manner in which it was acquired or used, and the surrounding circumstances. But an express statement that the recipient is “not accepting information in confidence” can be important evidence against a later contention that the recipient implicitly agreed to keep the information secret or restrict its use.

The practical rule therefore runs in both directions: the discloser should establish confidentiality before the technical discussion, while a recipient unwilling to accept confidentiality obligations should say so before receiving the information.

Pitfall No. 2: Filing a Patent Application Does Not Necessarily Make the Information Public; But Publication Does

Inventors sometimes misunderstand the relationship between patents and trade secrets. A confidential, unpublished patent application ordinarily is not the same thing as a public disclosure. But when the application publishes, information disclosed in it ordinarily enters the public domain.

Courts have repeatedly recognized this principle. The Seventh Circuit explained in BondPro Corp. v. Siemens Power Generation, Inc., 463 F.3d 702, 706-07 (7th Cir. 2006), that publication in a patent destroys trade-secret status for the disclosed information. The Ninth Circuit similarly held in Attia v. Google LLC, 983 F.3d 420, 425-26 (9th Cir. 2020), that disclosure of a trade secret in a published patent application extinguishes the trade-secret status of the disclosed information. The Federal Circuit has applied the same basic rule. See, e.g., ClearValue, Inc. v. Pearl River Polymers, Inc., 668 F.3d 1340, 1346 (Fed. Cir. 2012).

This creates an important timeline problem. Suppose:

January 2025: Inventor confidentially discloses information to Company.
March 2025: Company allegedly begins using that information.
September 2025: Negotiations terminate.
January 2026: Inventor’s patent application publishes.
March 2026: Company continues developing its competing product.

Publication in January 2026 may terminate trade-secret protection for information actually disclosed by the patent application. But it does not necessarily rewrite history. If the company improperly used secret information in March 2025, while it was still secret, the later publication does not necessarily make the earlier conduct lawful.

That can transform the dispute into a “head-start case”: what competitive advantage did the recipient obtain during the period in which the information remained secret?

Pitfall No. 3: A Patent May Disclose the Invention Without Disclosing All of the Know-How

The reverse mistake is assuming that once a patent publishes, every piece of information associated with the development program loses trade-secret protection. That is not necessarily true.

A patent might disclose a compound, dosage form, formulation range, method of treatment, or manufacturing process while leaving undisclosed substantial development know-how, including:

• failed formulations and negative experimental results;
• preferred excipient combinations or processing parameters;
• stability problems and solutions;
• impurity profiles and methods of controlling them;
• bioavailability or pharmacokinetic observations;
• target-selection criteria;
• unpublished animal or clinical data;
• manufacturing scale-up knowledge;
• analytical methods;
• regulatory strategy; or
• the particular combination of otherwise known information that allows a development program to proceed efficiently.

Courts therefore distinguish between information actually disclosed in a patent and additional proprietary information that goes beyond the patent disclosure. That distinction played an important role in the recent Biohaven Therapeutics Ltd. v. Avilar Therapeutics, Inc. litigation in Delaware. Yale researchers had filed patent applications concerning their MODA targeted protein degradation technology. Some alleged trade-secret information was later disclosed when the applications became public. But the plaintiffs alleged that other information, including development information not contained in the applications, remained confidential.

The court recognized the basic dividing line: information contained in a published patent or patent application ordinarily cannot remain a trade secret, but proprietary information going beyond the publication potentially can.

That produces an important litigation lesson: a plaintiff should be able to identify with specificity “what remained secret after the patent publication” rather than simply characterize an entire “technology” or “platform” as confidential.

Pitfall No. 4: The Inventor May Have Been His or Her Own Worst Enemy

Patent publication is only one form of public disclosure. Pharmaceutical and biotechnology inventors routinely speak at scientific meetings, publish abstracts and posters, submit journal articles, issue press releases, maintain websites, speak with potential investors, publish clinical-trial information, and present corporate slide decks. Each disclosure potentially narrows what remains secret.

This can produce an uncomfortable situation during litigation. The inventor may accuse the defendant of stealing “confidential” information only to encounter a chronology showing that substantially the same information appeared in the inventor’s own conference presentation, patent application, publication, poster, website, or other public disclosure.

The question then becomes granular: “What did the defendant allegedly use that was not already publicly available?”

That inquiry should occur before filing suit, not during discovery.

Public Pieces Can Sometimes Produce a Secret Combination

There is another important complication. A defendant cannot always defeat a trade-secret claim merely by locating each individual element somewhere in the public domain. In Brigham Young University v. Pfizer, Inc., 861 F. Supp. 2d 1320, 1325-26 (D. Utah 2012), the court considered an alleged compilation trade secret involving numerous elements relating to identification of COX-2 selective drugs. A combination of information may potentially qualify as a trade secret even though individual components are known, if the particular combination itself is not generally known or readily ascertainable and has economic value because of its secrecy.

But simply relabeling public information as a “combination” does not automatically restore secrecy. The plaintiff still must identify what is distinctive about the asserted combination and why someone using proper means could not readily assemble it.

The Head-Start Doctrine: Sometimes the Trade Secret Is Time

Pharmaceutical development is expensive partly because failure teaches. A company may spend years determining which formulation does not work, which excipient creates instability, which synthesis pathway creates an impurity, which dose produces unacceptable exposure, or which development strategy leads to a regulatory dead end.

Consequently, confidential negative information can be extraordinarily valuable. A competitor that legitimately begins at Point A may have to test ten alternatives before reaching Point K. A recipient of confidential information may allegedly be able to begin at Point J. In that circumstance, the economic value of the information may not simply be the ultimate formulation, compound, process, or development strategy. Its value may be the months or years of experimentation that the recipient no longer has to perform.

That is the essence of the trade-secret “head start” or “jump start” concept. In Oakwood Laboratories LLC v. Thanoo, 999 F.3d 892, 914 (3d Cir. 2021), the Third Circuit addressed allegations that confidential information concerning Oakwood’s sustained-release microsphere technology was provided to a competitor and used to “jump start” a competing development program. The court explained that actionable use of a trade secret can include relying on the information to assist or accelerate research or development. A plaintiff therefore need not necessarily wait until the recipient launches the competing product before alleging that the secret has been used.

Similarly, pharmaceutical information may derive economic value from secrecy precisely because obtaining the same knowledge independently could require years and millions of dollars. Jazz Pharmaceuticals, Inc. v. Synchrony Group, LLC, 343 F. Supp. 3d 434, 445-46 (E.D. Pa. 2018), illustrates that principle.

The head-start concept can also affect the scope and duration of a remedy. The question may be not whether the defendant must be excluded from the field forever, but how long it would have taken a legitimate competitor to reach the same position without the misappropriated information. In ams-OSRAM USA Inc. v. Renesas Electronics America, Inc., 133 F.4th 1337 (Fed. Cir. 2025), applying Texas trade-secret law, the Federal Circuit discussed a head-start period as the period of competitive or marketing advantage obtained by the misappropriator compared with a competitor that obtained the information through proper means. Likewise, Nite Glow Industries, Inc. v. Central Garden & Pet Co., 2021 WL 2945556 (Fed. Cir. July 14, 2021), illustrates the use of the time required for legitimate independent development in assessing a head-start period.

Consider a simplified pharmaceutical example. Assume that independent development normally would require 36 months of formulation screening, stability work, failed experiments, optimization, and confirmatory testing. If confidential information allows the recipient to reach the same point in 12 months, the alleged competitive benefit may be approximately 24 months of avoided development. If the relevant information later becomes publicly available through a patent publication, scientific publication, or other proper source, the recipient may thereafter be entitled to learn from that public information. But later public disclosure does not necessarily erase an unfair advantage already obtained while the information remained secret.

Thus, a later patent publication can create an important remedial question: “when would the recipient have reached the same point if it had waited for the information to become lawfully available and then developed the product without the earlier confidential disclosure?”

That question also prevents the doctrine from becoming overbroad. Trade-secret law should eliminate an improperly obtained competitive advantage; it should not ordinarily convert an expiring secret into perpetual exclusivity.

Development Speed Can Be Evidence; But It Is Not Itself Misappropriation

But the inference must not be reversed. Moving quickly does not itself prove theft.

A sophisticated company may have better financing, more scientists, better laboratories, experienced regulatory personnel, established CDMO relationships, or simply superior execution. It may legitimately reach in eighteen months what an underfunded inventor could not accomplish in five years.

Trade-secret law protects against misappropriation. It does not guarantee the original inventor a commercial lead. For that reason, development speed should be analyzed comparatively. The plaintiff should be prepared to explain what experiments, failures, costs, or delays the defendant allegedly avoided. The defendant, conversely, should be prepared to explain why its speed was achievable without the plaintiff’s information, for example, because of preexisting expertise, prior internal work, greater funding, larger scientific teams, parallel experimentation, established CDMO relationships, or reliance on published literature and patents. “We developed faster” is neither proof of theft nor a complete defense. The real question is “why” the defendant developed faster.

Biohaven v. Avilar: A Modern Warning From Both Sides of the Table

The recent Biohaven litigation provides a useful illustration. According to the allegations, Yale researcher Dr. David Spiegel developed technology involving targeted protein degradation and discussed the technology with RA Capital regarding a potential business arrangement. After an initial high-level discussion, Yale and RA Capital entered a confidential disclosure agreement restricting the use of confidential MODA information to evaluating a possible contractual relationship.

The parties exchanged information and negotiated potential financing, but negotiations ultimately failed. Plaintiffs subsequently alleged that RA Capital used confidential information to help establish a competing company, Avilar Therapeutics, and accelerate development of competing technology.

The defendants raised precisely the kinds of issues that commonly arise in these disputes: whether information had been publicly disclosed, whether particular information fell within the confidentiality agreement, whether reasonable secrecy measures had been taken, and what information remained secret after Yale’s patent applications published.

The court declined to dispose of the trade-secret claims at the pleading stage. In July 2026, a federal jury subsequently found Avilar and RA Capital liable for willful and malicious misappropriation of a Yale trade secret and found that RA Capital breached its confidentiality agreement with Yale, awarding $4 million.

The case demonstrates both sides of the problem. A confidentiality agreement can materially strengthen the discloser’s position. But patent publication and other public disclosures can materially narrow the universe of information that remains protectable. Ultimately, the case may turn not on ownership of a broad scientific “idea,” but on identifying the particular nonpublic information that was disclosed and allegedly used.

Cytokinetics v. MyoKardia/BMS: A Head Start Can Be Authorized and Patent Rights Raise a Different Problem

A recently filed pharmaceutical patent case illustrates the other side of the head-start concept. Cytokinetics, Inc. v. Bristol-Myers Squibb Co. and MyoKardia, Inc., filed in the District of Delaware in August 2026, is not a trade-secret action. Cytokinetics seeks declarations of noninfringement and invalidity of a MyoKardia patent. But the allegations provide a useful contrast because Cytokinetics itself describes having given MyoKardia a substantial development head start.

According to Cytokinetics’ complaint, Cytokinetics helped launch and incubate MyoKardia in 2012. Cytokinetics alleges that it licensed existing cardiac myosin inhibitors to MyoKardia and provided facilities, equipment, personnel, and know-how as part of a collaboration to discover and develop additional cardiac myosin inhibitors. Cytokinetics received research funding, milestones, and royalties in return. The collaboration allegedly produced mavacamten within months, and Cytokinetics says that the resulting “substantial head start” helped MyoKardia obtain FDA approval for CAMZYOS® before Cytokinetics obtained approval for its later-developed aficamten product, MYQORZO®.

The important point for trade-secret purposes is straightforward: “a head start is not inherently wrongful.” Technology licenses, sponsored research arrangements, collaborations, acquisitions, and development partnerships are often entered into precisely because one party can accelerate the other’s development. The relevant question is whether the recipient’s use was authorized by the parties’ agreement or exceeded the permitted scope.

The Cytokinetics dispute then raises a different but related issue: “what happens when a recipient of information later seeks patent rights that reach the original innovator’s technology?”

Cytokinetics alleges that MyoKardia filed a patent application directed broadly to methods of treating HCM using myosin inhibitors and identified aficamten even though, according to the complaint, MyoKardia had no role in aficamten’s discovery or development. Cytokinetics further alleges that after Cytokinetics publicly disclosed favorable aficamten clinical results and FDA approval approached, MyoKardia amended its claims to specifically recite aficamten. Cytokinetics challenges the resulting patent under Sections 102, 103, and 112, among other grounds.

Those allegations should not be confused with an adjudicated trade-secret or inventorship finding; they remain allegations in a newly filed patent case. But they highlight an issue that should be considered whenever technical information is shared with another company: the recipient may not merely develop a competing product; it may also file patent applications informed by what it learned.

That possibility implicates a different body of patent law. Patent inventorship turns on who conceived the claimed invention, not merely who filed the application, funded the work, received the information, or reduced it to practice. Depending on the facts, disputes may arise over inventorship, ownership, assignment obligations, derivation, validity, written description, enablement, or contractual provisions governing intellectual property created during or after a collaboration. A trade-secret plaintiff therefore should not assume that every dispute over a recipient’s later patent is a trade-secret claim; nor should a recipient assume that access to another party’s technical information necessarily makes the recipient an inventor of patent claims built upon that information.

This suggests another practical lesson: confidentiality agreements and collaboration agreements should address not only secrecy and permitted use, but also intellectual-property rights. Where appropriate, the agreement should address background IP, ownership of inventions arising from the relationship, patent filing rights, disclosure of inventions, and whether confidential information may be used in preparing or prosecuting patent applications.

Before Suing: Build the Disclosure Matrix

Before asserting pharmaceutical trade-secret misappropriation, counsel should consider constructing a detailed chronology or disclosure matrix. For every alleged trade secret, identify:

1. What is the secret? Define the information specifically. “Our formulation technology” or “our development platform” may be too abstract.
2. When was it created? Identify laboratory notebooks, reports, emails, protocols, datasets, presentations, and other contemporaneous evidence.
3. When and how was it disclosed to the recipient? Identify the document, meeting, email, data room, presentation, or conversation.
4. What confidentiality obligation existed at that moment? Identify the NDA, CDA, employment obligation, collaboration agreement, or facts supporting an implied duty.
5. When, if ever, did the information become public? Check patent publications, journal articles, abstracts, posters, conference presentations, websites, press releases, regulatory disclosures, and other sources.
6. What did the recipient allegedly do with it? Identify evidence connecting the information to the recipient’s development decisions rather than relying solely on similarity between the products.
7. What legitimate independent sources were available? Determine whether the same information could have come from patents, publications, vendors, consultants, employees, reverse engineering, or the recipient’s own research.
8. What head start did the information actually provide? Do not merely assert that the recipient “developed faster.” Establish the legitimate counterfactual development path. What experiments would have been required? What formulation iterations, stability studies, synthesis work, animal studies, clinical work, manufacturing development, or regulatory analysis would ordinarily have occurred? How much time and money did the recipient allegedly avoid?
9. Did the recipient file patent applications after receiving the information? Compare the claims and specifications against what was disclosed, when it was disclosed, who conceived the claimed subject matter, and what the recipient independently developed. Determine whether the governing agreements address inventions, ownership, assignment, patent prosecution, or use of confidential information in patent filings.

That exercise often reveals whether the dispute concerns genuine misappropriation or merely an inventor who lost the commercial race.

Practical Guidance for the Discloser

For inventors, universities, startups, and smaller pharmaceutical companies, several precautions can substantially improve the ability to protect valuable know-how.

1. File before disclosing, but remember that filing and secrecy are different concepts. A patent application can preserve patent rights while remaining confidential before publication. Carefully decide which information belongs in the patent application and which implementation know-how should remain protected as a trade secret.
2. Use a written confidentiality agreement before substantive disclosure. The agreement should restrict both disclosure and use and clearly define the permitted purpose. If the recipient refuses to sign a CDA, believe the refusal. An inventor should not proceed on the assumption that the information will somehow remain legally confidential because it is scientifically valuable, commercially sensitive, or obviously important. If the prospective recipient expressly states that it will not receive information in confidence, the inventor should limit the discussion to public or deliberately nonconfidential information, or decline to make the substantive disclosure. Sending the information anyway may substantially complicate a later argument that reasonable measures were taken to preserve secrecy or that the recipient assumed a duty restricting use.
3. Stage the disclosure. A potential partner usually does not need the entire technical package during the first meeting. Begin with nonconfidential or high-level information and disclose deeper technical information only after appropriate protections are in place.
4. Identify confidential material. Mark documents appropriately, control data-room access, maintain records of downloads, and memorialize important oral disclosures.
5. Maintain a disclosure log. Know who received what information, on what date, and under which agreement.
6. Coordinate scientific publication and patent strategy with trade-secret strategy. Before submitting an abstract, poster, paper, patent application, or investor presentation, ask what information will enter the public domain and what should remain confidential.
7. Address downstream patent rights before the disclosure. Particularly in collaborations or technical diligence that may evolve into joint development, consider whether the agreement should address background IP, newly conceived inventions, ownership, assignment, patent filing and prosecution, and use of the other party’s confidential information in patent applications. A confidentiality clause alone may not answer who owns a later invention or who may seek patent claims arising from the relationship.
8. Finally, protect the information like a trade secret before litigation begins. Courts examine whether the owner actually took reasonable measures to preserve secrecy. Calling something “confidential” for the first time in a complaint is considerably less persuasive than contemporaneous evidence demonstrating that it was treated that way throughout development.

Practical Guidance for the Recipient

Companies evaluating outside pharmaceutical opportunities face the opposite problem.

1. Decide whether you are willing to receive confidential information before receiving it. A company that routinely evaluates outside technologies should consider a formal submission policy. If it does not want confidentiality obligations at the preliminary stage, it should say so clearly: do not send trade secrets or other confidential information; absent an executed written CDA, submissions will not be received in confidence. The objective is not to obtain a license to appropriate someone else’s trade secrets. It is to prevent an unsolicited submission from later being characterized as having silently created a confidentiality relationship that the recipient never intended to accept.
2. Know what you are receiving. Separate nonconfidential introductory discussions from information received under an NDA or CDA. Consider documenting the transition. For example, initial discussions might expressly remain nonconfidential, with more detailed technical diligence beginning only after execution of a CDA. Or in any CDA/NDA, expressly state that confidential material exists only in written form and no confidentiality exists as to oral or verbal disclosures. This may avoid having to prove oral disclosures that cannot be corroborated.
3. Understand the permitted-use clause. Information supplied “solely to evaluate a potential transaction” may create substantial risk if personnel later use it to develop an internal competing program.
4. Control internal distribution. Do not circulate confidential diligence material indiscriminately among scientists who are developing competing technology.
5. Document independent development. Laboratory notebooks, dated development plans, literature searches, preexisting research, and contemporaneous technical records can become critical evidence that the company’s program arose independently.
6. Identify public sources contemporaneously. If a development decision is based on a published patent, scientific paper, conference abstract, or other public source, preserve that evidence. A litigation position constructed five years later is less persuasive than a contemporaneous record showing what the development team actually consulted.
7. Consider clean-team procedures. Where a company is already pursuing adjacent technology, business-development personnel evaluating an outside opportunity may need to be separated from scientists conducting the internal competing program.
8. Preserve evidence of an express nonconfidential submission. If the sender was told before disclosure that the company would not accept confidential information, preserve the email, submission terms, portal acknowledgment, meeting invitation, or other record reflecting that understanding. A verbal warning may be helpful, but a contemporaneous written record is far better evidence years later.
9. Police patent filings as carefully as product development. If employees or scientists exposed to another party’s confidential information participate in later patent drafting, document the conception of the claimed inventions and the lawful sources of the technical information relied upon. Where the company is already working in an adjacent field, consider whether clean-team or other procedures should extend to patent strategy as well as laboratory development.
10. And most importantly, do not assume that because information eventually appeared in a patent application, everything learned earlier under an NDA automatically became fair game. Timing matters.

The Bottom Line: Trade Secret Law Protects Secrets, Not Lost Opportunities

Pharmaceutical innovators understandably become frustrated when someone they approached for financing or collaboration later succeeds in developing a competing product. But chronology alone does not establish misappropriation:

Inventor develops concept → Company learns of concept → Company develops competing product

is not enough.

The legally important chronology is more demanding:

Inventor possesses specifically identifiable nonpublic information → Inventor takes reasonable measures to preserve its secrecy → Company receives that information subject to a duty restricting its use → Company improperly uses the information → Company thereby obtains a development advantage.

When those facts exist, a pharmaceutical “head start” can represent valuable evidence of trade-secret misappropriation.

When they do not, the explanation may be much simpler. The second company may have seen the same opportunity, raised money faster, executed better, and won the race.

And sometimes the recipient’s head start was expressly authorized, as Cytokinetics alleges occurred when it helped incubate MyoKardia. In still other cases, the dispute may migrate from trade-secret law into patent law because the recipient later seeks patent claims allegedly derived from, or reaching, the discloser’s technology. Those situations require separate attention to conception, inventorship, ownership, validity, and the parties’ contractual allocation of intellectual-property rights.

The Moral of the Story

Trade-secret law prohibits stealing the shortcut. It does not prohibit running faster.